Cross-colonisation with *Pseudomonas aeruginosa* of patients in an intensive care unit

Dennis C J J Bergmans, Marc J M Bonten, Frank H van Tiel, Carlo A Gaillard, Siebe van der Geest, Rob M Wilting, Peter W de Leeuw, Ellen E Stobberingh

**Abstract**

*Background*—Ventilator-associated pneumonia (VAP) caused by *Pseudomonas aeruginosa* is usually preceded by colonisation of the respiratory tract. During outbreaks, colonisation with *P aeruginosa* is mainly derived from exogenous sources. The relative importance of different pathways of colonisation of *P aeruginosa* has rarely been determined in non-epidemic settings.

*Methods*—In order to determine the importance of exogenous colonisation, all isolates of *P aeruginosa* obtained by surveillance and clinical cultures from two identical intensive care units (ICUs) were genotyped with pulsed field gel electrophoresis.

*Results*—A total of 100 patients were studied, 44 in ICU 1 and 56 in ICU 2. Twenty-three patients were colonised with *P aeruginosa*, seven at the start of the study or on admission and 16 of the remaining 93 patients became colonised during the study. Eight patients developed VAP due to *P aeruginosa*. The incidence of respiratory tract colonisation and VAP with *P aeruginosa* in our ICU was similar to that before and after the study period, and therefore represents an endemic situation. Genotyping of 118 isolates yielded 11 strain types: eight in one patient each, two in three patients each, and one type in eight patients. Based on chronological evaluation and genotypical identity of isolates, eight cases of cross-colonisation were identified. Eight (50%) of 16 episodes of acquired colonisation and two (25%) of eight cases of VAP due to *P aeruginosa* seemed to be the result of cross-colonisation.

*Conclusions*—Even in non-epidemic settings cross-colonisation seems to play an important part in the epidemiology of colonisation and infection with *P aeruginosa*.

(Thorax 1998;53:1053–1058)

**Keywords:** colonisation; *Pseudomonas aeruginosa*; ventilator-associated pneumonia

Ventriculator-associated pneumonia (VAP) is the most important nosocomial infection among mechanically ventilated patients in intensive care units (ICUs) and is associated with increased morbidity and mortality, especially when caused by *Pseudomonas aeruginosa*. VAP is almost always preceded by colonisation of the upper respiratory tract with the causative microorganism. However, the exact routes of colonisation leading to VAP and the relative importance of different pathways of colonisation is a matter of controversy.

Respiratory tract colonisation with *P aeruginosa* may originate from endogenous sources such as the intestine or the stomach, or from exogenous sources such as contaminated equipment or other patients colonised with *P aeruginosa*. Understanding the relative importance of these routes of colonisation is crucial to the development of effective preventative measures against infection. If, for example, cross-colonisation occurs frequently, improved compliance with infection control measures will be necessary, but such a measure will be less effective if most infections are from endogenous sources. In the latter case, modulation of bacterial colonisation of the gastrointestinal tract may be more appropriate. The clinical observation of three episodes of VAP due to *P aeruginosa* in a short period of time was the starting point for the present study. Infection was assumed to be the result of cross-colonisation of microorganisms. In order to determine the importance of exogenous and endogenous colonisation of *P aeruginosa* we initiated an analysis of colonisation and infection with this pathogen.

**Methods**

The study was performed in two identical eight bed intensive care units (ICU 1 and ICU 2) of the University Hospital Maastricht, a 700 bed hospital. Both ICUs contained a mixed population of surgical, medical, and trauma patients who were randomly admitted. The units have different nursing staff and medical equipment, but the medical staff and paramedic care providers (physiotherapists, radiographic personnel, and the nutrition support team) have patient contacts in both ICUs. No outbreaks of multiple resistant microorganisms have occurred during the last five years.

**Patients**

All patients admitted to ICU 1 and ICU 2 (ventilated or non-ventilated) were studied prospectively with regard to respiratory tract colonisation and the development of VAP and other ICU acquired infections in two study periods: from 6 November 1993 to 15 December 1993 in ICU 1 (40 days) and from 17 November 1993 to 15 January 1994 in ICU 2 (60 days). The following data were recorded on admission: age, sex, medical specialty, length of time in hospital before admission to the ICU,
diagnosis on admission, reason for intubation, previous medical history, and APACHE II score.11 During the stay in the ICU clinical parameters (temperature, leucocyte count, chest radiographs) were recorded daily. All 16 mechanically ventilated patients receiving enteral nutrition with an expected duration of ventilation of ≥3 days were included in a prospective study on the influence of continuous and intermittent enteral feeding on respiratory and digestive tract colonisation.12 Another six patients were included in a study on sequences of colonisation within the patient.

SURVEILLANCE CULTURES
Patients were subjected to microbiological examination of endotracheal aspirates and urine on admission and then twice weekly. In addition, a more extensive examination was performed on the patients included in the two prospective studies mentioned above. Gastric aspirates and oropharyngeal swabs were cultured daily from the 16 patients in the study on the effects of intermittent enteral feeding, and from the six patients studied to determine sequences of colonisation cultures were obtained twice daily (08.00 and 16.00 hours) from six body sites (nose, oropharynx, sputum, gastric aspirate, rectum and groin) during their stay in the ICU. The results of all clinical cultures were also included in the analysis. No cultures were taken from non-intubated patients with an ICU stay of less than 24 hours.

DEFINITIONS
(1) Colonisation was defined as the isolation of microorganisms from specimens taken from any body site in the absence of infection. Colonisation on admission was defined as that occurring within 48 hours of admission to the ICU. When colonisation occurred more than 48 hours after admission to the ICU, without colonisation on admission, it was defined as acquired colonisation.

(2) Ventilator-associated pneumonia was diagnosed by bronchoscopy with protected specimen brush (PSB) and bronchoalveolar lavage (BAL). The diagnosis was established when (a) at least three of the following criteria were met: (i) rectal temperature above 38.0°C or below 35.5°C, (ii) blood leucocytosis (>10×10⁹/mm³) and/or left shift or blood leucopenia (<3×10⁹/mm³), (iii) more than 10 leucocytes per high power field in gram stain of tracheal aspirate, and (iv) a positive culture from a tracheal aspirate, in combination with (b) a new or progressive infiltrate on the chest radiograph, and (c) the presence of (i) a positive quantitative culture of a sample of secretions obtained by BAL (cutoff point ≥10⁵ cfu/ml) or PSB (cutoff point ≥10⁴ cfu/ml) or (ii) positive cultures from blood unrelated to another source obtained within 48 hours before and after respiratory sampling and with the same species as cultured from the tracheal aspirate, or (iii) positive pleural fluid culture in the absence of previous pleural instrumentation. Pneumonia was considered to be ICU-acquired if symptoms began ≥48 hours after admission to the ICU.

(3) Endogenous colonisation was defined as colonisation occurring with a strain of *P. aeruginosa* that had not previously been isolated from another patient.

(4) Exogenous colonisation or cross-colonisation was defined as colonisation occurring with a strain of *P. aeruginosa* with similar pulsed field gel electrophoresis (PFGE) typing results to that of isolates from another patient present in one of the ICUs.

COLONISATION PRESSURE AND ANTIBIOTIC PRESSURE
For each study day the point prevalence of *P. aeruginosa* colonisation in the ICU was calculated as follows: number of patients colonised with *P. aeruginosa* on that day divided by the total number of patients present in the ICU on that day. Subsequently, for each patient who was not colonised with *P. aeruginosa* on admission or at the start of the study, the mean point prevalence of *P. aeruginosa* colonisation for all days in the ICU until acquisition of *P. aeruginosa* or until discharge (if the patient did not acquire colonisation) was calculated. This calculated number reflects the colonisation pressure with *P. aeruginosa* for the period in the ICU that the patient was not colonised.

Antibiotic pressure was determined as follows: the percentage of days that non-colonised patients received antibiotic therapy that provided *P. aeruginosa* with a selective growth advantage ((aminopenicillins, first and second generation cephalosporins, macrolides, glycopeptides etc) was calculated until acquisition of *P. aeruginosa* or until discharge from the ICU.

MICROBIOLOGY AND BACTERIAL TYPING
Semi-quantitative microbiological analysis of surveillance and clinical cultures were performed and PSB and BAL samples were analysed qualitatively. All isolated species were identified according to methods routinely used in the medical microbiology laboratory. Specimens were inoculated immediately after sampling, seven days a week. From each culture plate with growth of *P. aeruginosa* three colonies were analysed and stored separately until further processing. All isolates of *P. aeruginosa* were stored at a temperature of −70°C. From each patient and each body site found to be colonised with *P. aeruginosa* isolates were randomly selected for bacterial typing.

The antibiotic susceptibility pattern was determined by measurement of minimal inhibitory concentrations using the micro-broth dilution method according to the NCCLS guidelines. *P. aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922 and 35218 were used as reference strains. Susceptibility to the following antibiotics was determined: piperacillin, coticarclavulanate, ceftazidime, imipenem, gentamicin, tobramycin, amikacin, ciprofloxacin, and ofloxacin. PFGE was carried out according to the method described by Grothues et al13 using a CHEF-DRII System (Bio-Rad Laboratories, Richmond, California, USA) after restriction digestion with SpeI (Boehringer Mannheim, Germany). *Saccharomyces cerevisiae* was used as a marker.
Table 1  Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>ICU 1</th>
<th>ICU 2</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients studied</td>
<td>44</td>
<td>56</td>
<td>100</td>
</tr>
<tr>
<td>Number of colonised patients</td>
<td>9</td>
<td>14</td>
<td>23</td>
</tr>
<tr>
<td>Prior to study period</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>On admission</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Acquired</td>
<td>4</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Number of pneumonias</td>
<td>5</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>61 (0–92)</td>
<td>61 (0–79)</td>
<td>61 (0–92)</td>
</tr>
<tr>
<td>Male/female</td>
<td>25/19</td>
<td>30/26</td>
<td></td>
</tr>
<tr>
<td>Median APACHE II score (range)</td>
<td>21 (5–33)</td>
<td>18 (2–41)</td>
<td>19 (2–41)</td>
</tr>
<tr>
<td>Medical specialty</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery/trauma</td>
<td>12</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Medical</td>
<td>10</td>
<td>17</td>
<td>27</td>
</tr>
<tr>
<td>Pulmonology</td>
<td>5</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Neurology/neurosurgery</td>
<td>7</td>
<td>10</td>
<td>17</td>
</tr>
<tr>
<td>Paediatrics</td>
<td>4</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Cardiology</td>
<td>3</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Mortality</td>
<td>13 (30%)</td>
<td>14 (25%)</td>
<td>27 (27%)</td>
</tr>
</tbody>
</table>

* Median (range) days in hospital before admission to ICU.

PFGE patterns were compared visually on enlarged gel photographs to identify bands of identical relative mobility as fragments of identical size. The absolute number of band differences between pairs of isolates was recorded. The criteria of Tenover et al** were used to interpret chromosomal DNA restriction patterns produced by PFGE for typing of bacterial strains. Indistinguishable isolates (no band differences) and closely related isolates (2–3 band differences) were considered to be the same genotype, while possibly related and different isolates (4–6 and 7 band differences, respectively) were considered different genotypes.

STATISTICAL ANALYSIS

Data are expressed as absolute numbers with or without percentages, as means with standard deviation (SD), or as medians with ranges. Frequency comparisons were performed by the Mann-Whitney test or \( \chi^2 \) test, a p value of less than 0.05 being considered statistically significant.

Results

In all, 100 patients were studied of whom 65 were mechanically ventilated. During the study period in ICU 1 (40 days) 44 patients were studied—40 were admitted and four were present at the start of the study. In ICU 2 (60 days) 56 patients were studied, 50 of whom were admitted and six were present at the onset of the study. The characteristics of the patients admitted to both ICUs were comparable (table 1). Furthermore, the occupancy rate of beds was similar in both ICUs, 91% in ICU 1 and 93% in ICU 2.

SURVEILLANCE OF COLONISATION

In all, 1370 specimens were taken from 73 patients (243 endotracheal aspirates, 159 urine samples, 383 blood/pus/intravascular lines, 47 urinary catheters, 28 PSB/BAL fluid samples, 199 oropharyngeal swabs, 40 rectal swabs, 191 gastric aspirates, 41 nose swabs, and 39 groin swabs). No cultures were taken from 27 patients because their stay in the ICU was less than 24 hours and they were not intubated. Most of these patients were postoperative neurosurgical patients and patients admitted after auto-intoxication. *P* aeruginosa was isolated from 69 specimens (22 endotracheal aspirates, two urine samples, 15 blood/pus/intravascular lines, three urinary catheters, seven PSB/BAL fluid samples, 11 oropharyngeal swabs, two rectal swabs, five gastric aspirates, one nose swab and one groin swab) obtained from 23 patients. Eight of them developed VAP. Surveillance cultures were positive for *P* aeruginosa before this species was isolated from clinical cultures in 77% of cases.

Colonised patients had a longer median duration on mechanical ventilation (17 versus 2 days, p<0.0001), but did not differ significantly with respect to the other characteristics (data not shown).

Four (4.4%) of the 90 patients admitted to the ICUs were colonised with *P* aeruginosa on admission, all of them in ICU 1. In addition, three out of 10 patients who were present in the ICU at the start of the study were already colonised, one in ICU 1 and two in ICU 2. Thus, 93 patients were not colonised with *P* aeruginosa at the onset of the study or on admission to the ICU, and 16 (17%) of them acquired colonisation with *P* aeruginosa, four of 39 in ICU 1 and 12 of 54 in ICU 2.

VENTILATOR-ASSOCIATED PNEUMONIA

During the study period eight (8%) of 100 patients developed VAP caused by *P* aeruginosa (table 1), three in ICU 1 and five in ICU 2, with a mean (SD) duration from admission to ICU to diagnosis of VAP of 7.3 (3.1) days. The incidence of VAP caused by *P* aeruginosa was 8% in the total study population. However, the incidence among ventilated patients was 12% (eight of 65) and 20% (eight of 41) for patients ventilated for 3 days. The overall incidence of VAP caused by *P* aeruginosa during the total study period was 0.9 per 100 patient days. In periods of two months the incidence of VAP caused by *P* aeruginosa ranged from 0.4 to 0.9 per 100 patient days in the year following the study period, suggesting that the incidence of VAP during the period of study was not exceptional in our ICU.

MICROBIOLOGICAL TYPING

In all, 118 isolates of *P* aeruginosa were genotyped, cultured from the following sites: 61 endotracheal aspirates, seven blood samples, two intravascular lines, 21 PSB/BAL fluid samples, 18 oropharynx, and nine stomach samples. In two patients (B and S) *P* aeruginosa was cultured only once during the stay in the ICU. Unfortunately these isolates were lost in the process of storage and could not be genotyped.

Antimicrobial susceptibility patterns were similar for isolates of all but one patient—that is, susceptible to piperacillin, ticarcilavulanate, cefazidime, imipenem, gentamicin, tobramycin, amikacin, ciprofloxacin and ofloxacin. One patient (J) was colonised with a strain of *P* aeruginosa resistant to...
gentamicin and tobramycin (type X), and such a strain was not isolated from any other patient. We assumed therefore that cross-colonisation with this strain did not occur and isolates from this patient were not genotyped. Using PFGE, 11 different genotypes could be distinguished (types 1–11). Eight genotypes were found in single patients only, whereas one genotype (type 2) was isolated from eight patients and two genotypes (type 3 and type 7) were isolated from three patients. Two patients (U and W) were colonised with two different genotypes each.

INCIDENCE OF CROSS-COLONISATION

Genotype 2 was isolated from eight patients, five in ICU 1 and three in ICU 2 (fig 1). Patient M (ICU 2) was colonised with genotype 2 at the start of the study. Patient T (ICU 1) acquired genotype 2, presumably via cross-colonisation from patient M. Subsequently, genotype 2 colonised patient O (ICU 1) and patient K (ICU 2). Since patients M and K were not in ICU 2 simultaneously, patient K most probably acquired genotype 2 via patient T in ICU 1. Acquisition of genotype 2 by patient D could have been the result of cross-colonisation with patients U or R from ICU 1 as donor, or with patient K in ICU 2 as donor. Patients K and D were in ICU 2 simultaneously, but cultures of patient D only became positive six days after discharge of patient K. This delay may have been caused by sampling error or because colonisation initially occurred in numbers below the detection threshold of culture techniques. Three other patients in ICU 1 were colonised with genotype 2 when they were admitted (patients Q, R and U). Two of them were admitted directly from the community and one patient had been admitted to a general hospital ward one day before ICU admission. Cultures from all three patients were taken within 24 hours of admission. In patient Q, admitted directly from the community, genotype 2 was cultured from the endotracheal aspirate on admission. This patient had been treated in the ICU four months earlier and was colonised with P aeruginosa during that time as well. Unfortunately no strains from that period were genotyped. Thus, four patients (T and O in ICU 1, and K and D in ICU 2) appeared to have acquired genotype 2 by cross-colonisation. At the start of the study patient H (ICU 2) was colonised with genotype 3. Subsequently, colonisation with this genotype was demonstrated in patient A (on the first day of the study) and patient I (both in ICU 2). Although cultures from patient I only became positive with genotype 3 after discharge of patients A and H, all three patients were treated simultaneously in ICU 2 for a number of days. Finally, patient C (ICU 2) acquired colonisation with genotype 7, presumably from an endogenous source. Subsequently, two other patients in ICU 2 (P and N) acquired colonisation with this genotype. All other patients acquired colonisation with a unique genotype which was therefore presumed to be derived from endogenous sources. In all, eight episodes of cross-colonisation were demonstrated (four patients with genotype 2, two patients with genotype 3, and two patients with genotype 7). Fifty percent of all patients acquiring colonisation with P aeruginosa did so via cross-colonisation, the other 50% most probably being colonised from endogenous sources. In two of eight patients with VAP caused by P aeruginosa, colonisation probably occurred via cross-colonisation. The three episodes of VAP within a short period of time that initiated this study were caused by three different genotypes of P aeruginosa.

Discussion

Our findings suggest that cross-colonisation may be an important route of colonisation and infection for P aeruginosa even when overall...
Cross-colonisation with *Pseudomonas aeruginosa* of patients in ICU

1057

VAP was also diagnosed by bronchoscopy,\textsuperscript{17–20} clinically ventilated patients.\textsuperscript{15} In a large study performed in 1992 and 1993 in our ICU the incidence of VAP was 22%, with *P aeruginosa* involved in 58% of patients (13% of all mechanically ventilated patients).\textsuperscript{16} The incidence of VAP has therefore remained fairly stable throughout the years. Moreover, the clinical observation of three episodes of VAP within a short period of time appeared to be caused by three different genotypes. The period under study therefore reflects our endemic setting and is not an outbreak. Comparison of incidence rates with those in other ICUs is difficult, mainly because of different patient populations. However, the incidence of VAP ranges from 15% to 24% in settings where VAP was also diagnosed by bronchoscopy,\textsuperscript{17–20} and the proportion caused by *P aeruginosa* varied from 14% to 55%.\textsuperscript{17–22}

Observations of similar genotypes of *P aeruginosa* colonising and infecting several patients strongly suggest the occurrence of cross-colonisation, not only between patients in the same ward but also between patients from different wards. Although contaminated equipment might have been a source, regular examinations of nebulisers and sinks were always negative for *P aeruginosa*, and the polyclonal character of the epidemiology make this possibility fairly unlikely.

The possibility of cross-colonisation of *P aeruginosa* in non-epidemic situations has rarely been studied. Olson and coworkers\textsuperscript{23} addressed this issue in a study of 270 patients admitted to a medical/surgical ICU ward; 63 (23%) patients were colonised with *P aeruginosa* on admission and 33 (16%) acquired colonisation, 12 of whom (36%) were found to be due to cross-colonisation. In a prospective surveillance study carried out in five ICUs during a six month period, Chetchoitisakd et al\textsuperscript{24} did not find an important role for cross-colonisation, only 14 (10%) of 137 isolates of bacteria (*P aeruginosa, E coli, Klebsiella pneumoniae, Enterobacter cloacae, enterococci*) cultured from patients with suspected infection being acquired by cross-colonisation. Although molecular biotyping methods were used to determine the identity of the isolates, they may have underestimated the true incidence of cross-colonisation. Only a single isolate from a suspected site of infection was analysed, without including isolates from colonised patients. It is evident that infections with *P aeruginosa* only form the tip of the iceberg of the complete epidemiology,\textsuperscript{25} and its epidemiology can only be studied reliably when surveillance of colonisation is included. Moreover, patients may be colonised or infected with multiple genotypes of *P aeruginosa*, and analysis of a single isolate will not accurately represent the whole epidemiology.\textsuperscript{25}

The difference in the number of cases of cross-colonisation between both ICUs in the present study (two in ICU 1 and six in ICU 2) may be associated with the higher colonisation pressure in ICU 2 compared with ICU 1. However, differences in compliance with infection control measures, which was not monitored, may be another explanation for this difference. Pressure was clearly higher for patients who acquired *P aeruginosa*. These findings suggest that both endogenous colonisation—for example, intestinal colonisation—and exogenous colonisation play a role in the epidemiology of respiratory tract colonisation with *P aeruginosa*. In this regard, the epidemiology of *P aeruginosa* may share similarities with endemic situations of other nosocomial pathogens such as vancomycin-resistant enterococci. These bacteria are also frequently acquired via cross-colonisation\textsuperscript{26} and their acquisition seems to be influenced by high colonisation pressure and a high antibiotic pressure, providing these bacteria with a selective growth advantage.\textsuperscript{27} However, the present study does not allow us to determine the precise relative impact of both exogenous and endogenous colonisation of *P aeruginosa*. Since the study was started abruptly after the clinical suspicion of cross-colonisation, surveillance was not uniform in all patients. More importantly, no surveillance cultures of the rectum were performed. Since rectal colonisation may be a source of respiratory tract colonisation,\textsuperscript{28} cases of endogenous colonisation may have been missed.

The relative importance of endogenous and exogenous colonisation in the pathogenesis of VAP therefore remains to be established.

The authors thank Monique Coomans and Christel Driessen for the microbiological analysis, and the medical and nursing staff of the ICU who helped to make this study possible. This study was supported in part by grant 20-2125-1 from the Prevention Foundation.


Cross-colonisation with *Pseudomonas aeruginosa* of patients in an intensive care unit

Dennis C J J Bergmans, Marc J M Bonten, Frank H van Tiel, Carlo A Gaillard, Siebe van der Geest, Rob M Wilting, Peter W de Leeuw and Ellen E Stobberingh

*Thorax* 1998 53: 1053-1058
doi: 10.1136/thx.53.12.1053

Updated information and services can be found at: [http://thorax.bmj.com/content/53/12/1053](http://thorax.bmj.com/content/53/12/1053)

These include:

References

This article cites 29 articles, 5 of which you can access for free at: [http://thorax.bmj.com/content/53/12/1053#BIBL](http://thorax.bmj.com/content/53/12/1053#BIBL)

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)

Notes

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)